Therapeutic drug monitoring in antituberculosis chemotherapy

Therapeutic Drug Monitoring

Volumn 20, Issue 5, 1998, Pages 469-472

  Yew, W W ^a  

^a GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

Antituberculosis drug monitoring

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; CYCLOSERINE; DIAZEPAM; DIGITOXIN; ENFLURANE; ENOXACIN; ETHAMBUTOL; ETHIONAMIDE; HALOPERIDOL; ISONIAZID; KANAMYCIN; KETOCONAZOLE; OFLOXACIN; PHENYTOIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; SULFONYLUREA; THEOPHYLLINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; WARFARIN;

ANTIBIOTIC THERAPY; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; LIVER TOXICITY; MYCOBACTERIOSIS; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT INDICATION; TUBERCULOSIS; UVEITIS;

ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; TUBERCULOSIS, PULMONARY;

EID: 0031711084     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199810000-00004     Document Type: Conference Paper

References (31)

1. Peloquin CA. Therapeutic drug monitoring: principles and applications in mycobacterial infections. Drug Therapy 1992;22:31-6.
2. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993;77:1253-62.
3. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87.
4. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 1992;327:1817-8.
5. Peloquin CA, Nitta AT, Burman WJ, Brudney KF. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-25.
6. Sahai J, Swick L, Tailor S, et al. Reduced oral absorption of tuberculosis drugs in HIV infection [abstract]. Clin Pharmacol Ther 1996;59:142.
7. Peloquin CA. Mycobacterium avium complex infection: pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes. Clin Pharmacokinet 1997;32:132-44.
8. Iseman MD, Madsen LA. Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance. Chest 1991;100:124-7.
9. Elliot AM, Berning SE, Iseman MD. Peloquin CA. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis 1995;76:463-7.
10. Woo J, Wong CL, Teoh R, Chan K. Liquid Chromatographic assay for simultaneous determination of pyrazinamide and rifampicin in serum samples from patients with tuberculous meningitis. J Chromatogr 1987;420:73-80.
11. Walubo A, Chan K, Wong CL. Simultaneous assay for isoniazid and hydrazine metabolite in plasma and cerebrospinal fluid in the rabbit. J Chromatogr 1991;567:261-6.
12. Eule H. PAS. Tubercle 1973;54:165-7.
13. Kreukniet J, Blom Van Assendelft PM, Mouton PR, Tasman A, Bangma PJ. The influence of para-aminosalicylic acid on isonicotinic acid hydrazide blood levels after oral and intravenous administration. Scand J Respir Dis 1967;47:236-43.
14. Boman G. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. Eur J Clin Pharmacol 1974;7:217-25.
15. Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber Lung Dis 1993;74:87-90.
16. Mouton RP, Mattie H, Swart K, Kreukniet J, Wael J. Blood levels of rifampicin, desacetylrifampicin and isoniazid during combined therapy. J Antimicrob Chemother 1979;5:447-54.
17. Walubo A, Chan K, Woo J, Chan HS, Wong CL. The disposition of antituberculous drugs in plasma of elderly patients, II: isoniazid, rifampicin and pyrazinamide. Meth Find Exp Clin Pharmacol 1991;13:551-6.
18. Woo J, Chan C, Chan R, Cheung W, Or K, Chan K. Correlation between steady-state plasma concentrations of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters. J Med 1995; 26:279-94.
19. Grange JM, Winstanley PA, Davies PDO. Clinically significant drug interactions with antituberculosis agents. Drug Saf 1994;11: 242-51.
20. Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Ann Pharmacother 1995;29:1149-55.
21. Miller RR, Porter J, Greenblatt DJ. Clinical importance of the interaction of phenytoin and isoniazid. Chest 1979;75:356-8.
22. Patsalos PN, Duncan JS. Anti-epileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993;9:156-84.
23. Mazze RI, Woodruff RE, Heert ME. Isoniazid-induced enflurane defluorination in humans. Anesthesiology 1982;57:5-8.
24. Ellard GA. Chemotherapy of tuberculosis for patients with renal impairment. Nephron 1993;64:169-81.
25. Todd PA, Faulds D. Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991;42:825-76.
26. Acocella G, Bonollo L, Garimoldi M, Mainardi M, Tenconi LT, Nicolis FB. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 1972;13:47-53.
27. Steele MA, Burk RF, Des Prez, RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991;99:465-71.
28. Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 1975;18:70-9.
29. Jenner PJ, Ellard GA. Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle 1989;70:93-101.
30. Sarma GR, Immanuel C, Kailasam S, Narayana ASL, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. Am Rev Respir Dis 1986;133:1072-5.
31. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment with short-course regimens containing isoniazid, rifampicin and pyrazinamide for tuberculosis. Tubercle 1986;67:99-108.